Radius Health (RDUS) Misses Q2 EPS by 6c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Maxim Group Downgrades Radius Health (RDUS) to Sell
August 4, 2016 2:15 PM EDTMaxim Group downgraded Radius Health (NASDAQ: RDUS) from Hold to Sell with a price target of $24.00.
Analyst Jason McCarthy commented:
RDUS is "back" to an overvalued state. As such we are downgrading to Sell, from Hold. While we continue to believe that Abaloparatide-SC (and eventually the transdermal patch) will likely gain approval in 2017 in both the U.S. (PDUFA March 30, 2017) and Europe (EMA opinion early 2017), we believe significant challenges lay ahead in penetrating a mature Forteo Market, competition from Biosimilar Forteo in 2018 (from Teva [TEVA-$53.57-Buy]) and patients opting for alternative... More